A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer.
Amit M OzaMaria Del Pilar Estevez DizEva-Maria GrischkeMarcia HallFrederic MarméDiane ProvencherDenise S UyarJohanne I WeberpalsRobert M WenhamNaomi LaingMichael TracyTomoko FreshwaterMark A LeeJi LiuJingjun QiuShelonitda RoseEric H RubinKathleen M MoorePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Establishing an optimal strategy for managing tolerability and identifying specific patient populations most likely to benefit from treatment may increase clinical benefit. Future studies should consider additional adavosertib doses within the chemotherapy treatment cycle and the potential for maintenance therapy.